[
  {
    "ts": "2026-01-21T12:58:00+00:00",
    "headline": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
    "summary": "Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.",
    "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cf79b557-1b48-3e1f-91da-c9a05b656b77",
      "content": {
        "id": "cf79b557-1b48-3e1f-91da-c9a05b656b77",
        "contentType": "STORY",
        "title": "Here's Why You Should Retain Revvity Stock in Your Portfolio for Now",
        "description": "",
        "summary": "Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.",
        "pubDate": "2026-01-21T12:58:00Z",
        "displayTime": "2026-01-21T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVTY"
            },
            {
              "symbol": "STE"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T15:49:00+00:00",
    "headline": "CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February",
    "summary": "CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.",
    "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f396ab58-8ebb-3737-848a-d6e2691d9e0b",
      "content": {
        "id": "f396ab58-8ebb-3737-848a-d6e2691d9e0b",
        "contentType": "STORY",
        "title": "CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February",
        "description": "",
        "summary": "CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.",
        "pubDate": "2026-01-21T15:49:00Z",
        "displayTime": "2026-01-21T15:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rR6iZHXu8FRY2qc4ebuBNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXlDKOevAW4cJAnlMECSwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/capr-updates-fda-deramiocel-bla-154900055.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STE"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]